Efficacy Study of Telbivudine in Chronic Hepatitis B Patients

This study will be multicenter, open-label and observational data collection of patients on telbivudine who meet baseline characteristics defined as the majority of patients seen in the clinic setting. Data collection will take place after enrollment, at Week 12, 24, 52, 76 and 104 for efficacy assessments. In patients who discontinue observational drug earlier, clinical information would be kept following for assessment as well.

Study purpose:

This study is designed to evaluate the efficacy of telbivudine in real-life clinical settings with the use of the Roadmap Concept in chronic hepatitis B treatment.

Objectives:

Primary:

To observe telbivudine's 2-year efficacy in real-world clinical setting of achieving HBV-DNA < 60 IU/ml and HBeAg seroconversion rate in patients with defined baseline characteristics and 24-week treatment PCR negativity as previously reported in GLOBE study's sub-analysis.

Secondary:

• To observe the treatment outcomes.
• To validate the result of super-responder trial.
• To validate the Roadmap Concept.

Population:

The study population will consist of a representative group of 500 chronic hepatitis B patients with detectable HBsAg for more than 6 months who need telbivudine therapy based on investigators' judgment in 16 medical centers located in Taiwan.

Inclusion criteria

• Male or female 18 to 65 years of age
• Documented chronic hepatitis B defined by ALL of following:

• Clinical history compatible with compensated chronic hepatitis B
• Detectable serum hepatitis B surface antigen (HBsAg)> 6 months and at the screening visit.

Exclusion criteria

• Pregnant or nursing
• co-infection with hepatitis C virus (HCV) or HIV
• Clinical or imaging diagnosis of cirrhosis
• Evidence of decreased renal function of creatinine >(=)2x ULN